StockData
Valneva SE logo

Valneva SE (VALN) stock

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30
$5.16−0.21 (-3.82%)

Close on Nov 20, 2026Market cap $447.73MP/E –Yield –

Valneva gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Valneva's gross profit for the twelve months ending Jun 30, 2026 was €23.44M, down 75.6% year over year. For fiscal 2025 it was €67.52M, down 5.0% from the year before. The highest annual figure on record is €160.17M in fiscal 2021.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025€67.52M-5.0%
FY2024Dec 31, 2024€71.04M+34.5%
FY2023Dec 31, 2023€52.84M+43.3%
FY2022Dec 31, 2022€36.86M-77.0%
FY2021Dec 31, 2021€160.17M+185.9%
FY2020Dec 31, 2020€56.02M-23.7%
FY2019Dec 31, 2019€73.42M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€1.60M-93.4%
Q1 FY2026Mar 31, 2026€4.72M-82.0%
Q4 FY2025Dec 31, 2025€11.62M-54.8%
Q3 FY2025Sep 30, 2025€5.50M-72.7%
Q2 FY2025Jun 30, 2025€24.21M+65.9%
Q1 FY2025Mar 31, 2025€26.19M+147.2%
Q4 FY2024Dec 31, 2024€25.71M+62.4%
Q3 FY2024Sep 30, 2024€20.15M+17.8%
Q2 FY2024Jun 30, 2024€14.59M+112.2%
Q1 FY2024Mar 31, 2024€10.59M-18.7%
Q4 FY2023Dec 31, 2023€15.83M–
Q3 FY2023Sep 30, 2023€17.10M-86.4%
Q2 FY2023Jun 30, 2023€6.88M–
Q1 FY2023Mar 31, 2023€13.03M+63.1%
Q4 FY2022Dec 31, 2022-€10.31M-104.1%
Q3 FY2022Sep 30, 2022€125.43M–
Q2 FY2022Jun 30, 2022-€86.24M-2173.6%
Q1 FY2022Mar 31, 2022€7.99M-6.7%
Q4 FY2021Dec 31, 2021€249.91M–
Q3 FY2021Sep 30, 2021-€102.46M–
Q2 FY2021Jun 30, 2021€4.16M–
Q1 FY2021Mar 31, 2021€8.57M–

More Valneva figures

See a number that looks wrong?